Introduction {#S1}
============

Schwann cells are the most abundant glial cells in the peripheral nervous system, ensheathing all axons of peripheral nerves as either myelinating or non-myelinating cells. In addition to its role as insulators of axons, Schwann cells are crucial for the proper function and maintenance of peripheral nerves by providing metabolic and/or trophic support ([@B10]; [@B32]; [@B104]) and modulating responses to nerve injury ([@B51]; [@B63]). Disrupting Schwann cell function can compromise glial--axon communication, nerve homeostasis, and ultimately lead to fiber loss, neurodegeneration, and pain. Although cellular and molecular mechanisms underlying communication between Schwann cells and dorsal root ganglia (DRG) neurons remain to be investigated, Schwann cell dysfunction could play a key role in the pathogenesis of peripheral neuropathy, a highly complex and prevalent disease affecting 2.4% of the general population. The prevalence of peripheral neuropathy increases with age, with 8% in individuals 55 years of age or older in Europe and 14.8% in individuals 40 years of age or older in United States ([@B78]; [@B37]). The causes of peripheral neuropathy, which may be hereditary or iatrogenic from the toxicity of drugs given as part of antiretroviral or chemotherapy regiments, are often secondary to systemic illnesses including diabetes and infectious causes such as human immunodeficiency virus type 1 (HIV-1).

Human immunodeficiency virus type 1 infection affects 35 million people worldwide. Although combined anti-retroviral therapy (ART) successfully suppresses HIV-1 and dramatically increases the lifespan of HIV-infected individuals, neurological complication of HIV-1 infection persists. Between 30 and 60% of HIV-infected individuals develop HIV-associated distal symmetric polyneuropathy (DSP), a peripheral sensory neuropathy that is characterized clinically by numbness, tingling, pain, paresthesia, and allodynia that begin in distal lower extremities symmetrically and extend to more proximal areas and the upper extremities later in the disease ([@B19]). Pathologically, DSP is characterized by loss of intraepidermal nerve fibers, nerve fiber swelling, mononuclear inflammation, distal degeneration of long axons in a "dying back" pattern and concurrent damage to the DRG ([@B105]; [@B14]; [@B59], [@B5]; [@B96]). The pathogenesis of DSP was originally attributed to neurotoxic effects of HIV-1 infection, but this is likely to be an indirect effect because evidence of viral infection of sensory neurons is lacking ([@B62]; [@B82]). Since the introduction of ART, sensory neuropathy resulting from neurotoxic antiretrovirals, especially stavudine (d4T), didanosine (ddI), and zalcitabine (ddC), commonly referred to as d−drugs, has been recognized. However, in resource-rich countries where these neurotoxic drugs are no longer widely used, the rate of HIV-1 sensory neuropathies remains unsatisfactorily high ([@B29]; [@B69]). Furthermore, the prevalence of HIV-1 DSP was high before the introduction of highly active antiretroviral therapy ([@B39]; [@B35]).

The pathogenesis of DSP remains elusive, but several underlying mechanisms have been proposed ([@B105]; [@B111]; [@B96]); peripheral nerve degeneration could result from HIV-induced dysfunction of macrophages that release inflammatory mediators, from age-related HIV-comorbidities such as diabetes, or from neurotoxicity of gp120, a glycoprotein on the HIV-1 envelope. Although gp120 is able to bind to DRG neurons and may have a direct neurotoxic effect ([@B3]; [@B82]; [@B121]; [@B12]; [@B122]), Schwann cell-dependent DRG neurotoxicity of gp120 has also been implicated; gp120 can bind to chemokine receptors (CXCR4) of Schwann cells and the subsequent release of chemokines can induce apoptosis of DRG neurons via the activation of the C-C chemokine receptor type 5 (CCR5) ([@B62]; [@B82]). However, vicriviroc, a CCR5 antagonist, did not improve pain compared to placebo in a trial of 118 patients with HIV DSP ([@B127]). Thus, further mechanistic studies of HIV DSP are warranted.

Lysosomes are acidic organelles responsible for the degradation of macromolecules derived from endocytic and autophagic substrates. Besides their classical role in degradation, lysosomes have been implicated in intercellular communications via lysosome exocytosis; lysosomes can respond to extracellular stimuli by docking at the interior of the cell surface, fuse with the plasma membranes, and release their contents. In the nervous system, lysosomal exocytosis represents as a new pathway for gliotransmitters secreted from astrocytes ([@B130]; [@B71]; [@B73]). In Schwann cells, lysosome exocytosis has also been demonstrated ([@B20]; [@B107]; [@B57]; [@B114]) and lysosome exocytosis can play an important role in regulating myelination and the release of ATP, an important mediator of peripheral pain via activation of purinergic receptors ([@B115]; [@B42]; [@B125]; [@B58]; [@B128]). Thus, disturbances in Schwann cell function could be an important underlying factor for axonal degeneration as occurs in HIV-1 neuropathy ([@B94]; [@B120]; [@B10]; [@B6]; [@B84]; [@B15]).

Based on recent findings in non-neural cells that ATP is transported to lysosomes by the vesicular nucleotide transporter (VNUT), where it regulates lysosomal P2X4 function ([@B17]; [@B131]; [@B86]; [@B85]), we investigated the role of gp120 in regulating lysosome exocytosis in Schwann cells and subsequently affecting DRG neuron function. We demonstrated that gp120 induced the movement of lysosomes toward the cell periphery, increased lysosomal exocytosis, and enhanced release of ATP from Schwann cells, and that these processes were sensitive to P2X4 and VNUT inhibition. Using a simplified model of Schwann cell-DRG neuron interaction, we further showed that gp120-induced lysosomal exocytosis in Schwann cells increased cytosolic calcium and generation of reactive oxygen species (ROS) in DRG neurons. Our finding suggests that gp120-induced lysosome exocytotic release of ATP from Schwann cells contributes to the pathogenesis of HIV DSP.

Materials and Methods {#S2}
=====================

Cell Culture {#S2.SS1}
------------

Primary human schwann cells (hSCs) were obtained from ScienCell (Carlsbad, CA, United States). The hSCs were cultured in Schwann Cell Medium supplemented with Schwann Cell Growth Supplement, 10% Fetal Bovine Serum and 1% Pen/Strep, and maintained at 37°C in a 5% CO~2~ atmosphere following manufacturer's instructions. For the present study, only cells from passage 2--5 were used.

Rat Schwannoma RT4-D6P2T cells were obtained from ATCC (Manassas, VA, United States) and maintained in DMEM supplemented with 10% FBS. For the present study, only cells from passage 2--5 were used.

Rat embryonic DRG neurons were obtained from Lonza (Walkersville, MD, United States), and cultured according to manufacturer's instructions. Rat DRG neurons were cultured in primary neuron basal medium (PNBM) supplemented with 2 mmol/L L-Glutamine, 50 μg/ml Gentamicin/37 ng/ml Amphotericin, and 2% NSF-1. To get a pure DRG neuron culture without Schwann cells, mitotic inhibitors (17.5 μg/ml uridine and 7.5 μg/ml of 5-fluoro-2′-deoxyuridine) were added. DRG neurons were used for assay between DIV 7--10.

Plasmids and Transfection {#S2.SS2}
-------------------------

The P2X4-pHluorin123 plasmid was a kind gift from Baljit Khakh (Addgene plasmid \# 52926). The construct is based on the mouse P2X4 sequence, with the initiating methionine of pHluorin at position 123 of the reconstructed P2X4 receptor ([@B124]). The extracellular domain of P2X4 was chosen for pHluorin insertion because it avoided regions of known function. The total size of the insert was 1953 bp and was cloned into pcDNA3.1. For transient expression, RT4 Schwann cells were plated onto poly D-lysine coated 6-well plates at a density of 7000 cells/cm^2^ and transfected with 1.0 μg plasmid and 3.0 μL Lipofectamine 2000 transfection reagent at ∼70% confluency. On reaching confluency, cells were then split on to 35 mm^2^ poly D-lysine coated glass bottom dishes (MatTek) and imaged after 48--72 h.

Antibodies and Reagents {#S2.SS3}
-----------------------

The following primary antibodies were used in immunofluorescent staining; rabbit anti-LAMP1-CD107a (1:100 for surface staining, AB2971, EMD Millipore), rabbit anti-LAMP1-D2D11 (1:250 for intracellular staining, Catalog \#9091, Cell Signaling), mouse monoclonal anti-pan cadherin (1:500, Catalog \# C1821, Sigma-Aldrich), rabbit anti-TFEB (1:250, Catalog \# AV100809, Sigma-Aldrich), goat anti-VNUT (1:200, Catalog \# ABN110, EMD Millipore), rabbit anti-P2X4 (1:500, Catalog \# AB5226, EMD Millipore), rabbit anti-RILP (1:250, Catalog \# ab128616, Abcam). Alexa Fluor 594 goat anti-rabbit, 488 goat anti-rabbit, 594 goat anti-mouse, 488 goat anti-mouse antibodies were from Thermo Fisher, and Donkey Anti-Goat IgG Alexa 488 was from Abcam. All secondary antibodies were used at 1:250 dilutions.

Recombinant HIV-1 MN gp120 (Baculovirus) was from ImmunoDX (Catalog \# 1021), and heat -inactivated gp120 was used as a control. Acid Phosphatase Activity Fluorometric Kit was from Sigma-Aldrich (Catalog \# MAK087).

PKH 26 Red Fluorescent Cell Linker Kit was from Sigma-Aldrich (Catalog \# PKH26GL). Magic Red Cathepsin B kit was from Bio-Rad (Catalog \# ICT937). Lysotracker DND-99 Red (Catalog \# L7528), Thermo Fisher) was used at a final concentration of 50 nmol/L, Alexa Fluor 647 Dextran (Catalog \# D22914, Thermo Fisher) was used at a final concentration of 10 μg/ml, BODIPY FL ATP (Catalog \# A12410, Thermo Fisher) was used at 5 μmol/L, Fluo-8 AM (Catalog \# ab142773, Abcam) was used at 2 μmol/L, and H2DCFDA (Catalog \# D399, Thermo Fisher) was used at 5 μmol/L.

Bx430 was from Tocris Bioscience (Catalog \#5545), ATP disodium salt was from Sigma-Aldrich (Catalog\# FLAAS-5VL), and clodronate disodium salt and BzATP triethylammonium salt were from Calbiochem (Catalog \# 233183 and 5057340001, respectively).

Acid Phosphatase Activity Assay {#S2.SS4}
-------------------------------

Human schwann cells were plated on to poly-D-lysine coated 24-well plates at a density of 10,000 per cm^2^ and treated with either recombinant gp120 or heat-inactivated gp120 (as control) for 24 h or 40 min. The media supernatant (500 μL) was collected and 110 μL were used per sample (in triplicates) for acid phosphatase activity assay following manufacturer's instructions. Acid phosphatase activity was expressed as relative fluorescence, which was measured at Ex/Em-360/440 nm in a Spectra Max Plate Reader (Molecular Devices, San Jose, CA, United States).

LAMP1 Surface Staining {#S2.SS5}
----------------------

Human schwann cells were plated on to poly-D-lysine coated coverslips in 24-well plates at a density of 5000 per cm^2^ and treated with either recombinant gp120 or heat-inactivated gp120 (as control) for 40 min. The plate was chilled on ice and washed twice with ice-cold PBS (containing 1 mM CaCl~2~, 2 mM MgCl~2~) and LAMP1 antibody CD107a was added in 0.1% BSA in PBS for 30 min on ice. Following three washes with ice-cold PBS, plasma membranes were co-stained with PKH26 (4 μL/mL) for 90 s on ice. The cells were then washed three times with PBS, fixed in 4% PFA for 3 min on ice, and stained with secondary antibody (0.1% BSA in PBS) for 30 min. Coverslips were then washed, and mounted on frosted glass slides (Fisher Scientific) with ProLong Gold antifade (Catalog \# P36935, Thermo Fisher) before imaging on a Zeiss LSM800 Confocal Microscope.

Surface Biotinylation Assay {#S2.SS6}
---------------------------

Human schwann cells grown on poly-D-lysine coated 100 mm^2^ dishes were washed twice with PBS (Ca^+2^, Mg^+2^ free) and treated with recombinant gp120 (8.3 nM) or heat-inactivated gp120 (control) for 40 min. Following the treatments, cells were washed twice with ice-cold PBS and incubated with sulfo-NHS-SS-Biotin (0.5 mg/ml, 4°C, 30 min) and washed with quenching buffer (20 mM Tris and 120 mM NaCl, pH = 7.4) three-times to remove unreacted biotin. After washing twice with ice-cold PBS, hSCs were lysed with 200 μL of radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitor cocktail (Catalog \# A32963, Pierce, Thermo Fisher) followed by sonication. After centrifugation (10,000 × *g* for 10 min), supernatants were collected, and protein concentrations were determined with a DC protein assay (Bio-Rad). Further steps were followed as per Pierce Cell Surface Protein Isolation Kit (Catalog \# 89881, Thermo Fisher). Labeled proteins were isolated with NeutrAvidin Agarose columns and eluted with sample buffer before immunoblotting. LAMP1 levels were normalized to pan-Cadherin levels for analysis.

Immunoblotting {#S2.SS7}
--------------

Cells were harvested and lysed in 1 × RIPA lysis buffer (Thermo Fisher) plus 10 mM NaF, 1 mM Na~3~VO~4~, and Protease Inhibitor Cocktail (Pierce). After centrifugation (13,000 × *g* for 10 min at 4°C), supernatants were collected, and protein concentrations were determined with a DC protein assay (Bio-Rad). Proteins (10 μg) were separated by SDS-PAGE (12% gel) and transferred to polyvinylidene difluoride membranes (Millipore). The membranes were incubated overnight at 4°C with appropriate primary and secondary antibodies. The blots were developed with enhanced chemiluminescence, and bands were visualized and analyzed by LI-COR Odyssey Fc Imaging System. Pan-Cadherin or GAPDH was used as loading control to normalize LAMP1/P2X4 and TFEB levels, respectively. Quantification of results was performed by densitometry and the results were analyzed as total integrated densitometric volume values (arbitrary units).

ATP Measurement {#S2.SS8}
---------------

ATP released from hSCs into extracellular media was measured with ATP Bioluminescent Assay Kit (Catalog \# FLAA, Sigma-Aldrich) following manufacturer's instructions. ATP levels were expressed as relative luminescence, which was measured using a Spectra Max Gemini EM plate reader (Molecular Devices).

Immunofluorescence {#S2.SS9}
------------------

Human schwann cells seeded onto poly-D-lysine coated coverslips were treated with gp120 or heat-inactivated gp120 (control) and washed twice with PBS, and fixed with 4% PFA (Electron Microscopy Sciences) for 30 min at RT. The cells were then permeabilized with 0.01% Tween-20, washed twice with PBS and blocked with 3% BSA + 1% normal goat serum for 90 min at 4°C. Incubations with primary antibodies were done overnight at 4°C followed by two washes with PBS and incubation with secondary antibody for 90 min at 4°C. Coverslips were then washed and mounted on frosted glass slides (Fisher Scientific) with ProLong Gold antifade with DAPI before imaging on a Zeiss LSM800 confocal microscope. Controls for immunostaining specificity included staining neurons with primary antibodies without fluorescence-conjugated secondary antibodies (background controls), and staining neurons with only secondary antibodies; these controls helped eliminate auto-fluorescence in each channel and bleed-through (crossover) between channels. For live cell imaging, hSCs on poly D-lysine coated 35 mm^2^ glass bottom petridishes (MatTek, P35GC-0-10-C) were transduced with BacMam Lysosome GFP for 36 h prior to imaging. Time lapse imaging with z-stacks at 2 min intervals were captured using a Zeiss LSM800 confocal microscope. Images were processed using ZEISS ZEN and Imaris 9.2 software.

Cathepsin B Magic Red Assay {#S2.SS10}
---------------------------

Human schwann cells were transduced with BacMAM cytosolic GFP (Thermo Fisher) for 36 h and loaded with Alexa Fluor 647 dextran (10 kDa) for 6 h, followed by a chase of 3 h. Cells were then stained with Cathepsin B Magic Red (Bio-rad) as per manufacturer's instructions before imaging. 25--30 cells were imaged per treatment, and experiments were repeated in triplicate. Images were analyzed in Imaris with the cell and peripheral lysosome constructed as mentioned. The number of peripheral lysosomes colocalizing with Cathepsin B were quantified and expressed as a percentage relative to controls.

BODIPY FL-ATP Staining {#S2.SS11}
----------------------

Human schwann cells on coverslips were transduced with BacMam lysosome RFP for 36 h, then treated and stained with BODIPY FL-ATP in media (5 μmol/L) for 30 min at 37°C, washed twice with PBS and imaged. The lysosome RFP-positive vesicles were analyzed by Imaris and classified as peripheral, juxtanuclear, or perinuclear lysosomes. Their percentages corresponding to control were then plotted in GraphPad Prism 6.0.

DRG Neuron-Schwann Cell Conditioned Media Assay {#S2.SS12}
-----------------------------------------------

Rat Schwannoma cells (RT4-D6P2T) grown on poly-D-lysine coated coverslips were treated with gp120 in the presence/absence of inhibitors or controls for 30 min. Of 500 μL of the extracellular media, 200 μL was used for acid phosphatase or ATP assays to confirm lysosomal exocytosis. 100 μL of the conditioned media was added to 100 μL of Fluo-8/H2DCFDA stained primary rat DRG neurons (day 10 in culture), thus having a 1:1 ratio of conditioned media:DRG neuron media. Intracellular calcium and cytosolic ROS in DRG neurons were measured with a Zeiss LSM 800 confocal microscope.

Calcium Measurement {#S2.SS13}
-------------------

For Fluo-8 calcium imaging, DRG neurons were stained with Fluo-8 (2 μmol/L for 30 min at 37°C) in 1× assay buffer (HHBS with Pluronic F127 plus), followed by two washes with PBS and re-suspension in 100 μL of media prior to being taken for Schwann cell conditioned media assay. Imaging was done at Ex/Em - 490/525 nm with a 63X oil immersion lens. 25--30 cells were imaged per treatment, and the experiments were repeated in triplicate. Images were analyzed in Image J with the mean fluorescence intensity of cells (chosen as ROI) expressed as percentage. Control values were set at 100.

ROS Measurement {#S2.SS14}
---------------

Cytosolic ROS was measured by staining DRG neurons with H~2~DCFDA (5 μmol/L for 30 min at 37°C), followed by two washes and re-suspension in 100 μL of media before being taken for Schwann cell conditioned media assay. Imaging was done in the FITC channel. 25--30 cells were imaged per treatment, and the experiments were repeated in triplicate. Images were analyzed in Image J with the mean fluorescence intensity of cells (chosen as ROI) expressed as percentage. Control values were set at 100.

LAMP1-Positive Vesicle Positioning {#S2.SS15}
----------------------------------

Confocal microscopy acquired z-stack images were analyzed and processed in Imaris 9.2 (Bitplane, Zurich, Switzerland). LAMP1/RILP/BODIPY FL-ATP-positive vesicles were processed as spots, and the nucleus as surface using the Imaris for Cell Biologists module. The distance transformation in surface function was used to create inward facing concentric surfaces from the plasma membrane, and Imaris XT was used to calculate the number of spots. All image acquisition and analytical parameters (size, thresholding) were kept the same between experiments. Particle based colocalization was carried out for all experiments.

Statistical Analysis {#S2.SS16}
--------------------

All data were expressed as means ± SD. Statistical significance between two groups was analyzed with a Student's *t-*test, and statistical significance among multiple groups was analyzed with one-way ANOVA plus a Tukey *post hoc* test. *p* \< 0.05 was considered to be statistically significant.

Results {#S3}
=======

HIV-1 gp120 Induces Lysosomal Exocytosis {#S3.SS1}
----------------------------------------

Characteristic hallmarks of lysosomal exocytosis are increased release of lysosomal hydrolases into extracellular media and the translocation of lysosomal membrane proteins to the plasma membrane (PM) ([@B130]; [@B81]). Using these hallmarks, we determined the extent to which gp120 affects lysosomal exocytosis in primary hSCs. Release of lysosomal hydrolases into extracellular media was quantified by measuring activity of acid phosphatase in the media. Incubation of hSCs with recombinant HIV-1 gp120 for 24 h resulted in a concentration-dependent increase in release of lysosomal acid phosphatase into media ([Figure 1A](#F1){ref-type="fig"}). Under these conditions, gp120 treatment did not induce significant cell death, as indicated by no changes in levels of released LDH ([Figure 1B](#F1){ref-type="fig"}). A shorter treatment for 40 min with 8.3 nmol/L of HIV-1 gp120 also led to significant increase in acid phosphatase release into media ([Figure 1C](#F1){ref-type="fig"}). This shorter treatment was therefore used for all subsequent experiments. The PM translocation of LAMP1 was assessed by surface biotinylation assay, and PM levels of LAMP1 were normalized to a control PM protein (α-cadherin). We demonstrated that gp120 (8.3 nmol/L) treatment for 40 min significantly increased PM protein levels of LAMP1 ([Figure 1D](#F1){ref-type="fig"}). Furthermore, the PM translocation of LAMP1 was also assessed with surface staining of LAMP1, and levels of surface expression of LAMP1 was calculated as the ratio of LAMP1 immunofluorescent signal to total PM fluorescent signal as labeled with PKH26. gp120 (8.3 nmol/L) treatment for 40 min significantly increased surface expression of LAMP1 ([Figure 1E](#F1){ref-type="fig"}). Together, these findings indicate that gp120 induces lysosomal exocytosis in hSCs.

![HIV-1 gp120 induces lysosomal exocytosis in primary human Schwann cells (hSCs). **(A)** Compared to heat inactivated gp120 (control), gp120 caused a concentration-dependent increase in the activity of acid phosphatase in media of hSCs (*n* = 5, ^\*^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001). **(B)** HIV-1 gp120 did not change release of LDH in hSCs. **(C)** gp120 treatment (8.3 nmol/L for 40 min) significantly increased the release of acid phosphatase in the media of hSCs (*n* = 3, ^\*^*p* \< 0.05). **(D)** In surface protein biotinylation assay, gp120 treatment (8.3 nmol/L for 40 min) increased PM levels of LAMP1 (*n* = 3, ^∗∗∗^*p* \< 0.001). **(E)** In surface protein labeling assay, gp120 treatment (8.3 nmol/L for 40 min) increased PM of LAMP1 (*n* = 3, ^∗∗^*p* \< 0.01; bar = 15 μm).](fncel-13-00329-g001){#F1}

HIV-1 gp120 Induces Redistribution of Lysosomes {#S3.SS2}
-----------------------------------------------

Lysosome exocytosis requires two sequential steps. First, lysosomes are recruited to the close proximity of the cell surface (docking), and second, the pool of pre-docked lysosomes then fuses with the PM and releases lysosomal contents ([@B1]; [@B77]). The molecular trafficking machinery involved in these two steps is only partially known. To further determine mechanisms by which gp120 affects lysosomal exocytosis, we determined the effects of gp120 on the positioning of LAMP1-positve lysosomes. hSCs were treated with gp120 (8.3 nmol/L) for 40 min and stained with LAMP1 antibodies. Z-stacks were acquired every 0.4 μm in order to approximately position each lysosome in a single z plane. These images were then reconstructed in three dimensions with Imaris software; the cell boundary was either labeled by pan-cadherin antibodies or drawn from DIC images. As illustrated in [Figure 2A](#F2){ref-type="fig"} concentric shells of 2 μm diameter were constructed, moving radially inward from the PM toward the nucleus, and labeled as Shell 1, 2, and 3. The lysosomes in Shell 1, 2, and 3 were labeled as peripheral, juxtanuclear, and perinuclear, respectively. As shown in [Figure 2B](#F2){ref-type="fig"}, gp120 treatment increased the percentage of both peripheral and juxtanuclear lysosomes and decreased the percentage of perinuclear lysosomes. These findings indicate that gp120 causes a redistribution of LAMP1-positive lysosomes; lysosomes moving from the perinuclear to peripheral positions as a result of gp120 treatment. Given that these static images might not capture the dynamics of lysosomal exocytosis, we tracked the movement of LAMP1-positive lysosomes using live cell imaging. In hSCs transduced with LAMP1-GFP, gp120 promoted lysosomes trafficking to the PM, as indicated by increased number of LAMP1-positive lysosomes in the outermost Shell 1 ([Supplementary Figure S1A](#DS1){ref-type="supplementary-material"}). To rule out the possibility that the percentage changes of LAMP1-positive lysosomes in three shells is not a result of changes in lysosome biogenesis, total numbers of LAMP1-positive vesicles were quantified by immunostaining with LAMP1 antibodies. Treatment with gp120 (8.3 nmol/L) for 40 min did not change total number of LAMP1 positive vesicles ([Figure 2C](#F2){ref-type="fig"}). Treatment with gp120 (8.3 nmol/L) for 40 min did change total protein levels of TFEB, a key transcription factor that regulates the biogenesis of lysosome and autophagy ([Figure 2D](#F2){ref-type="fig"}). Furthermore, nuclear translocation of TFEB was determined with immunostaining, and gp120 (8.3 nmol/L) treatment for 40 did not induce significant change in nuclear translocation of TFEB ([Supplementary Figure S1B](#DS1){ref-type="supplementary-material"}). Together, these results indicate that gp120 induces lysosomal exocytosis in hSCs. Thus, our findings suggest that gp120 enhances the trafficking of lysosomes toward cell surfaces and promotes lysosomal exocytosis.

![HIV-1 gp120 causes lysosomal redistribution in hSCs. **(A)** Classification scheme of LAMP1 positive lysosomes in concentric shells labeled as peripheral (0--2 μm from PM), juxtanuclear (2--4 μm from PM), and perinuclear (\>4 μm from PM) lysosomes. **(B)** As shown in representative LAMP1 staining (insert) and 3D reconstructed images, gp120 treatment (8.3 nmol/L for 40 min) increased the percentage of peripheral (green) and juxtanuclear (magenta) lysosomes and decreased the percentage of perinuclear (yellow) lysosomes. Plasma membranes were outlined with Pan-Cadherin (red) and the nucleus stained with DAPI (blue). **(C)** gp120 treatment (8.3 nmol/L for 40 min) did not change total numbers of LAMP1 positive lysosomes (*n* = 100) **(D)** gp120 treatment (8.3 nmol/L for 40 min) did not change TFEB protein levels in hSCs.](fncel-13-00329-g002){#F2}

HIV-1 gp120-Induced Redistribution of Lysosomes Display Functional Heterogeneity {#S3.SS3}
--------------------------------------------------------------------------------

A recent study has shown that perinuclear lysosomes are more acidic and have higher cathepsin L activity than peripheral lysosomes ([@B55]). This heterogeneity could be due to the stabilization of the v-ATPase subunit V1G1 by rab interacting lysosomal protein (RILP), a downstream effector of Rab7 that links Rab7 to dynein--dynactin and controls retrograde transport of late endosomes and lysosomes ([@B54]). To further understand the underlying mechanism by which gp120 affects lysosome trafficking and lysosomal exocytosis, we determined the effects of gp120 on the colocalization of LAMP1 with RILP in hSCs. We found that gp120 (8.3 nmol/L) treatment for 40 min significantly lowered the association of RILP with peripheral lysosomes upon gp120 treatment but increased the association for juxtanuclear lysosomes ([Figure 3A](#F3){ref-type="fig"}). These findings are consistent with our observations that gp120 induced the movement of lysosomes from the juxtanuclear to the peripheral position and enhanced lysosomal exocytosis. Following upon others' observations that peripheral lysosomes are de-acidified compared to juxtanuclear and perinuclear lysosomes ([@B55]), we assessed pH-dependent lysosome degradative capacity using a Magic Red Cathepsin B assay. This assay utilizes a fluorogenic substrate of the lysosomal hydrolase Cathepsin B, which is active under acidic pH, and loses activity upon de-acidification. The amount of fluorescence is therefore a direct output of active Cathepsin B, indicating the acidification status of the lysosome ([@B72]; [@B21]). For this assay, hSCs were transfected with cytosolic GFP, and pulsed with Alexa Fluor 647 dextran (10 kDa) for 6 h followed by a chase of 3 h in order for the dextran to travel via the endocytic pathway to lysosomes. The hSCs were then treated with gp120 (8.3 nmol/L) for 40 min, stained with Magic Red Cathepsin B and imaged live by confocal microscopy. As expected, peripheral lysosomes had significantly lower levels of Magic Red fluorescence, indicating decreased activity of cathepsin B ([Figure 3B](#F3){ref-type="fig"}). These findings indicate that the altered distribution of lysosomes upon gp120 treatment could be attributed to lysosome de-acidification. To further test the extent to which reduced v-ATPase activity and lysosome de-acidification promotes lysosome exocytosis, we treated cells with bafilomycin, a specific v-ATPase inhibitor, and determined the distribution of LAMP1-positive lysosomes. LAMP1 positive lysosomes were analyzed for their distance from the PM (cells outlined by Pan-Cadherin labeling) using the same methods as mentioned earlier in [Figures 2C,D](#F2){ref-type="fig"}. Similar to that of gp120, treatment with bafilomycin increased the percentage of both peripheral and juxtanuclear lysosomes and decreased the percentage of perinuclear lysosomes ([Supplementary Figure S2](#DS1){ref-type="supplementary-material"}).

![HIV-1 gp120-induces redistribution of lysosomes displays functional heterogeneity. **(A)** gp120 treatment (8.3 nmol/L for 40 min) significantly decreased colocalization of LAMP1 (green) with RILP (red) in peripheral lysosomes, but increased colocalization of LAMP1 with RILP in juxtanuclear lysosomes (*n* = 3, ^\*^*p* \< 0.05, ^∗∗∗^*p* \< 0.001). **(B)** As shown in representative confocal (inset) and reconstructed Imaris images, gp120 treatment (8.3 nmol/L for 40 min) significantly reduced Cathepsin B activity (red) in peripheral (white) lysosomes (*n* = 3, ^∗∗∗^*p* \< 0.001).](fncel-13-00329-g003){#F3}

P2X4 Is Involved in gp120-Induced Lysosomal Exocytosis {#S3.SS4}
------------------------------------------------------

Although lysosomes are recruited to being in close proximity to the cell surface in a Ca^2+^-independent manner ([@B100]; [@B1]; [@B49]), the fusion of pre-docked lysosomes with the PM requires Ca^2+^ elevation. Mounting evidence indicate that calcium released from lysosomes could mediate such a fusion event, and recently studies have shown that P2X4 cationic channels are localized to both plasma membranes and lysosomes and is regulated by its natural ligand ATP in a pH-dependent manner ([@B18]; [@B27]). Thus, gp120-induced lysosomal exocytosis could result from activation of P2X4 cationic channels. To determine the involvement of P2X4 channel in gp120-induced lysosomal exocytosis, we first characterized the subcellular localization of P2X4 in hSCs. We demonstrated that P2X4 channels colocalized with LAMP1-positive lysosomes in hSCs ([Figure 4A](#F4){ref-type="fig"}). Using a surface biotinylation assay, we demonstrated that gp120 (8.3 nmol/L) treatment for 40 min increased PM levels of P2X4 ([Figure 4B](#F4){ref-type="fig"}), indicating the involvement of P2X4 in gp120-induced lysosome exocytosis. To further confirm the role of P2X4 in gp120-induced lysosomal exocytosis, pre-incubation with Bx430, a selective allosteric antagonist of P2X4 ([@B4]), significantly blocked gp120-induced increases in release of lysosomal acid phosphatase ([Figure 4C](#F4){ref-type="fig"}). We further determined the effect of a P2X4 agonist 2,3′-O-(4-benzoyl)benzoyl-ATP (BzATP) on lysosomal exocytosis ([@B30]; [@B113]). Similar to gp120, BzATP (5.0 μmol/L for 30 min) promoted lysosome exocytosis as indicated by increased activity of acid phosphatase released in media ([Supplementary Figure S3](#DS1){ref-type="supplementary-material"}). Thus, gp120 could induce lysosomal exocytosis by activating lysosomal P2X4 channels, and it is possible that gp120 affects the activity of P2X4 within the lumen of lysosomes because gp120 can be endocytosed ([@B11]; [@B122]). In support, we demonstrated that significant amounts of exogenous gp120-FITC trafficked to lysosomes in as early as 30 min with a Pearson's coefficient of 0.456 ([Supplementary Figure S4B](#DS1){ref-type="supplementary-material"}). It is known that the acidic pH of lysosome lumen has been shown to inhibit P2X4 channels ([@B46]). Therefore, upon gp120 treatment, lysosomes might move to the periphery, their luminal pH might increase (de-acidification), and as a result P2X4 receptors might be activated. To test this hypothesis, rat Schwannoma cells (RT4-D6P2T) were co-transfected with P2X4-tagged with pH sensitive fluorescent pHluorin123 and LAMP1-RFP. The pHluorin is a pH-sensitive GFP variant, the fluorescence of which remains quenched at acidic pH and increases as the pH increases to neutral ([@B124]). Cells co-transfected with P2X4-pHluorin123 and LAMP1-RFP were treated with gp120 (8.3 nmol/L) and imaged by time lapse microscopy for 20 min. As expected, gp120 increased P2X4-pHluorin123 fluorescence ([Figure 4D](#F4){ref-type="fig"}), indicating gp120 de-acidifies P2X4 positive lysosomes. To confirm that RT4 rat Schwann cells behave the same as that of primary hSCs in response to gp120 treatment, we determined the effect of gp120 on lysosome exocytosis in RT4 rat Schwann cells. We found that the response of these rat Schwann cells to gp120 was similar to that of primary hScs; gp120 increased the release of lysosomal acid phosphatase in media of rat Schwann cells ([Supplementary Figure S4A](#DS1){ref-type="supplementary-material"}).

![Lysosomal P2X4 channel is involved in HIV-1 gp120 induced lysosomal exocytosis. **(A)** Representative confocal and reconstructed Imaris images show P2X4 (red) is colocalized with LAMP1 (green) positive lysosomes in hSCs (bar = 20 μm). **(B)** In surface biotinylation assay, gp120 treatment (8.3 nmol/L for 40 min) increased P2X4 translocation to the PM in hSCs (*n* = 3, ^∗∗∗^*p* \< 0.001). **(C)** An allosteric P2X4 regulator Bx430 (0.5 μmol/L) prevented gp120 (8.3 nmol/L for 40 min)-induced increases in the activity of acid phosphatase release in media of hSCs (*n* = 3, ^\*^*p* \< 0.05, ^∗∗^*p* \< 0.01). **(D)** As shown in RT4 rat Schwann cells co-transfection of P2X4-pHluorin123 (GFP) and LAMP1-RFP (bar = 10 μm), gp120 treatment (8.3 nmol/L for 40 min) increased fluorescence of P2X4-pHluorin123 (*n* = 3, ^∗∗∗^*p* \< 0.001).](fncel-13-00329-g004){#F4}

HIV-1 gp120 Modulates Lysosomal P2X4 via VNUT ATP Transporter {#S3.SS5}
-------------------------------------------------------------

Lysosomal P2X4 activity has been shown to be dually regulated by luminal pH and ATP. One of the key lysosomal ATP transporters identified is VNUT (Vesicular Nucleotide Transporter or SLC17A9), responsible for ATP transport into lysosomes. VNUT has been shown to play a role in lysosomal exocytosis leading to extracellular release of ATP. To determine the involvement of VNUT in gp120-induced lysosome exocytosis, the lysosomal localization of VNUT in hSCs was first confirmed by immunocytochemistry, showing that 85% of LAMP1-positive lysosomes co-localized with VNUT, measured using mander's colocalization coefficient (MCC) in Imaris software ([Figure 5A](#F5){ref-type="fig"}). Importantly, pretreatment with clodronate, a specific allosteric inhibitor of VNUT, blocked gp120-mediated acid phosphatase release ([Figure 5B](#F5){ref-type="fig"}) as well as ATP release ([Figure 5C](#F5){ref-type="fig"}) into the extracellular media ([@B60]). To further determine the involvement of lysosomal ATP in gp120-induced lysosomal exocytosis, we visualized directly lysosomal ATP and their redistribution upon gp120 treatment. Here, hSCs were transduced with LAMP1-RFP, labeled with BODIPY FL-ATP and imaged upon gp120 treatment. The majority of BODIPY FL-ATP staining was observed to be in the lysosomes. To determine the redistribution of lysosomal ATP, cell boundaries were drawn from DIC images and vesicles positive for both LAMP1 and BODIPY FL-ATP were classified based on their distance from the PM as mentioned earlier. As shown in [Figure 5D](#F5){ref-type="fig"}, gp120 treatment resulted in a significant increase in the percentage of ATP positive lysosome in peripheral and juxtanuclear regions. Combined, these results suggest that lysosome de-acidification and ATP-mediated P2X4 activation could be a key process in gp120-induced lysosomal exocytosis.

![Lysosomal ATP transporter-VNUT mediates HIV-1 gp120 induced lysosomal exocytosis. **(A)** Representative confocal images and scatterplot show the colocalization of VNUT (green) with LAMP1 (red) positive lysosomes in hSCs (bar = 15μm). **(B)** Inhibiting VNUT with clodronate (Clo, 0.1 μmol/L) prevented gp120 (8.3 nmol/L for 40 min)-induced increases in the activity of acid phosphatase release in media of hSCs (*n* = 3, ^∗∗^*p* \< 0.01). **(C)** gp120 treatment (8.3 nmol/L for 40 min) increased ATP levels in media of hSCs, and this effect was prevented by inhibiting VNUT with clodronate (Clo, 0.1 μmol/L) (*n* = 3, ^∗∗^*p* \< 0.01. **(D)** As shown in representative Imaris reconstructed and confocal images (inset), gp120 (8.3 nmol/L for 40 min) increased percentage of ATP (BODIPY FL-ATP, green) in peripheral and juxtanuclear lysosomes (LAMP1-RFP) (*n* = 3, ^∗∗^*p* \< 0.01).](fncel-13-00329-g005){#F5}

HIV-1 gp120-Induced Schwann Cell Lysosomal Exocytosis Affects DRG Neuron Physiology {#S3.SS6}
-----------------------------------------------------------------------------------

To further determine whether gp120-induced lysosomal exocytosis in Schwann cells could affect the function of DRG neurons and contribute to HIV neuropathy, conditioned media of Schwann cells was used for treatment of DRG neurons. Here, RT4 rat Schwann cells were treated with HIV-1 gp120 for 45 min in the presence or absence of P2X4 blocker (Bx430) and VNUT inhibitor (clodronate), and the extracellular media was added to primary rat DRG neuronal cultures in a 1:1 ratio. Given that a rise in intracellular calcium and increasing the excitability of DRG neurons has been linked to heightened nociceptive sensation in neuropathic pain ([@B65]; [@B22]; [@B126]), we measured intracellular calcium of DRG neurons with Fluo-8. We found that gp120-treated Schwann cell conditioned media elevated intracellular Ca^2+^ in DRG neurons, whereas conditioned media from P2X4 and VNUT inhibition (by Bx430 and clodronate, respectively) failed to induce a rise in intracellular calcium ([Figure 6A](#F6){ref-type="fig"}). These findings indicate that gp120-induced lysosomal exocytosis of ATP in hSCs could be a key factor causing intracellular calcium to rise in DRG neurons. To further assess DRG neuronal function, cytosolic ROS was measured by staining with DCF-DA. As shown in [Figure 6B](#F6){ref-type="fig"}, incubation with gp120-treated Schwann cell conditioned media significantly increased DRG neuron ROS levels, whereas conditioned media from P2X4 and VNUT inhibition (by Bx430 and clodronate, respectively) failed to induce a rise in ROS levels. Because lysosomes have been shown to store ATP, which can be released upon exocytosis in other cell types ([@B130]; [@B108]; [@B9]) and we found that gp120 increased the release of ATP into media ([Figure 5](#F5){ref-type="fig"}), we determined effects of exogenous ATP on intracellular Ca^2+^ and ROS in DRG neurons. We found that ATP treatment increased both cytosolic Ca^2+^ and ROS in DRG neurons in a concentration-dependent manner ([Supplementary Figures S5A,B](#DS1){ref-type="supplementary-material"}).

![HIV-1 gp120 conditioned RT4 Rat Schwann cell media increases cellular calcium and ROS in DRG neurons. **(A)** gp120 conditioned Schwann cell media, but not gp120 + Bx430 or gp120 + Clo conditioned media, increased intracellular calcium levels as measured by Fluo-8 in rat DRG neurons (*n* = 3, ^∗∗^*p* \< 0.01). **(B)** gp120 conditioned media, but not gp120 + Bx430 or gp120 + Clo conditioned media, increased cytosolic ROS levels as measured by DCF-DA in rat DRG neurons (*n* = 3, ^∗∗^*p* \< 0.01).](fncel-13-00329-g006){#F6}

Discussion {#S4}
==========

HIV-associated distal symmetric polyneuropathy (DSP) is the most common neurological complication of HIV infection that results in chronic debilitating neuropathic pain. There is an urgent need for better understanding of its pathogenesis and for the development of effective therapeutic strategies. In the present study, we demonstrated that HIV-1 gp120 promoted the movement of lysosomes toward plasma membranes followed subsequently by lysosomal exocytosis and release of ATP; this process is achieved by gp120-induced activation of lysosome P2X4 via lysosome de-acidification and VNUT coupling. Such gp120-induced lysosomal exocytosis and release of ATP from Schwann cells induced increases in cytosolic calcium and ROS in DRG neurons. Our results suggest that gp120-induced lysosomal exocytotic release of ATP might signal through P2X4 and VNUT in Schwann cells and thereby contribute to the pathogenesis of HIV-DSP.

The HIV-1 envelope glycoprotein gp120, which is non-covalently attached to the transmembrane gp41 protein, is expressed on the outer layer of the virus. As such, gp120 is readily shed from HIV-1 virions and infected cells ([@B36]; [@B67]; [@B123]). Detectable levels of gp120 in plasma (0.5--15.6 ng/ml) and in spleen and lymph node (\>0.3 ng/ml) is present in HIV-1 infected individuals ([@B93]; [@B103]; [@B101]). Even in HIV-infected individuals under ART with no detectable viral replication, gp120 can be detected in lymph nodes ([@B95]). As the HIV-1 envelope protein, gp120 is critical for virus infection, because it is necessary for binding to specific cell surface receptors (CD4, CXCR4, and CCR5) on target cells and facilitating virus entry ([@B26]). Released free gp120 is a potent HIV virotoxin via either indirect mechanisms whereby gp120 promotes the release of pro inflammatory cytokines or other neurotoxic factors that elicit indirect neurotoxic effect ([@B61]; [@B13]), or direct mechanisms whereby gp120 elicits direct neurotoxic effect in the absence of glutamate receptor activation or pro-inflammatory cytokines ([@B8]; [@B7]; [@B122]).

The role of gp120 in the pathogenesis of HIV-DSP has long been recognized. Higher levels of gp120 in the spinal dorsal horn of HIV neuropathic pain-positive individuals provides a clue that gp120 plays an important role in the development of HIV DSP ([@B129]). Exposure of peripheral nerves to HIV-1 gp120 results in neuropathic pain ([@B43]). HIV gp120 transgenic mice or rodents treated with gp120 develop neuropathic pain with pathological similarities with humans such as peripheral neuropathy, pain behavior, synaptic degeneration and activation of glial cells ([@B89]; [@B92]; [@B121]; [@B40]; [@B16]). Similar to gp120-induced neurotoxicity in CNS, gp120 could elicit direct neurotoxicity on DRG neurons ([@B3], [@B2]) gp120 could activate macrophages, which in turn release neurotoxic inflammatory mediators that lead to indirect neurotoxicity, or gp120 acts on Schwann cells to release RANTES, which leads to DRG neurotoxicity via CCR5 activation ([@B62]; [@B82]).

Additionally, there is evidence that organelle damage, such as mitochondrial dysfunction ([@B68]) and endoplasmic reticulum dysfunction ([@B44]), contributes to the development of HIV DSP. However, virtually nothing is known about the involvement of lysosomes, which not only plays an important role in intercellular communication via lysosome exocytosis in CNS ([@B130]; [@B71]; [@B73]) but also play an important role in regulating Schwann cell function such as regulating myelination and the release of ATP, an important mediator of peripheral pain ([@B20]; [@B106]; [@B15]). As such, we determined the extent to which and mechanisms by which gp120 affects lysosomal exocytosis in Schwann cells and contributes to HIV neuropathy.

Mechanism of gp120-Induced Lysosome Exocytosis in Schwann Cells {#S4.SS1}
---------------------------------------------------------------

By measuring increased release of lysosomal hydrolases (acid phosphatase) into extracellular media and the translocation of lysosomal membrane proteins (LAMP1) to the PM, we demonstrated that gp120 promoted lysosome exocytosis in human Schwann cells. Because lysosomes docking (calcium independent) near the PM and subsequent fusion (calcium-dependent) with the PM are the two key steps to lysosome exocytosis ([@B1]; [@B49]; [@B119]), we then determined the extent to which gp120 affected lysosome positioning, an important factor mediating cellular homeostasis including autophagy, apoptosis, exosome release and metabolic signaling ([@B64]; [@B28]; [@B53]). To estimate lysosomal positioning, we used published methods of classifying them as perinuclear, juxtanuclear, or peripheral lysosomes based on their distances from the PM in concentric rings ([@B31]; [@B55]). Here, we used an increased ring diameter of 2 μm owing to the large size of hSCs, and we demonstrated that short-term treatment (40 min) with gp120 did not change total numbers of LAMP1-positive lysosomes but increased the numbers of peripheral and juxtanuclear lysosomes with concurrent decrease in the numbers of perinuclear lysosomes. Thus, gp120 increases the docking of lysosomes near the PM, which is consistent with enhanced lysosome exocytosis.

Lysosome trafficking in polarized cells occurs along microtubules and is mediated by plus-end directed kinesin ([@B45]) and minus-end directed dynein motors ([@B41]) that are controlled by the action of GTPases such as Rab proteins ([@B97]; [@B66]). Rab7 is a specific marker for late endosomes-lysosomes ([@B33]; [@B83]), and its downstream effector protein RILP induces recruitment of lysosomes to the dynein-dynactin complex preventing further cycling of Rab7 ([@B56]). Here, we showed that gp120 decreased the association of peripheral lysosomes with RILP, thus further supporting the concept that gp120 promotes the trafficking of lysosomes progressing toward exocytosis ([@B55]). We also demonstrated that gp120 increased the association of RILP with juxtanuclear lysosomes, which indicated that only the peripheral lysosomes undergo exocytosis. We further show that gp120 decreased cathepsin B activity in these peripheral lysosomes. Given that cathepsin B is more active in acidic environment, our findings are consistent with recent findings that lysosomes undergo progressive de-acidification as they move toward the PM ([@B55]), and possibly these peripheral lysosomes have fulfilled their degradative functions and are destined for exocytosis.

Upon further investigating the underlying mechanisms whereby gp120 affects lysosomal trafficking to the cell periphery and lysosome exocytosis, we determined the involvement of P2X4, a fast and sensitive purinergic receptor that preferentially localizes to lysosomes ([@B124]) and its activity is dually regulated by intra-lysosome pH and intra-lysosome ATP ([@B46]; [@B18]). In the present study we did not focus on other purinergic receptors, such as P2X7 that have been implicated in modulating lysosomal pH ([@B117]; [@B38]) because it has been shown that P2X7 receptors have ER and PM localization rather than lysosomes ([@B88]) owing probably to its longer C-terminal ([@B109]). We show that P2X4 is localized to LAMP1 vesicles in hSCs, an observation that is consistent findings in rat Schwann cells ([@B114]). Importantly, blocking P2X4 with specific human P2X4 antagonist Bx430 attenuated gp120-induced lysosomal exocytosis. The activity of lysosomal P2X4 is normally inhibited under acidic luminal pH ([@B46]). As lysosomes undergo alkalization while moving toward the PM ([@B55]), the de-acidification of lysosomes could activate P2X4. Using P2X4-pHluorin 123 construct, whose fluorescence increases with increasing pH, we demonstrated that gp120 treatment increased the fluorescence signal of lysosomes expressing P2X4-pHluorin 123, indicating gp120 increases lysosome pH (de-acidification).

However, increased lysosome pH itself is not sufficient to activate P2X4 as it is under the dual regulation of luminal pH and ATP. Consistent with others' findings ([@B107]), we demonstrated that lysosomes serve as ATP rich stores. Importantly, we demonstrated that gp120 treatment increased the percentage of ATP rich peripheral lysosomes. Thus, this population of ATP rich, de-acidified peripheral lysosomes is ideal for P2X4 activation, which probably reflects the calcium dependent second step of lysosomal exocytosis. We further showed that the ATP transporter VNUT was responsible for Schwann cell lysosomal ATP filling as inhibiting VNUT prevented gp120-induced lysosomal exocytosis and ATP release in the extracellular media. Thus, consistent with a report that functional coupling of VNUT and P2X4 underlies lysosome exocytosis ([@B131]), our findings indicate such a functional coupling of VNUT and P2X4 receptors play a role in gp120 induced lysosomal exocytosis. It is well known that lysosomal exocytosis is a calcium-dependent process; increases in intracellular calcium has been shown to promote the fusion of lysosomes within the vicinity of the PM and induce lysosomal exocytosis ([@B49]). Calcium released via P2X4 receptors may also contribute to gp120-induced lysosomal exocytosis. Activation of PM P2X4 receptors allows the influx of Ca^2+^ leading to increased intracellular Ca^2+^. Apart from calcium influx across PM, intracellular Ca^2+^ can be also increased via calcium released from lysosome lumen upon lysosomal P2X4 activation ([@B18]). Thus, calcium influx across PM and calcium release from lysosomes could both contribute to HIV-1 gp120-induced lysosomal exocytosis.

Together, our findings suggest that gp120 promotes the movement of lysosomes toward plasma membranes and subsequent lysosome exocytosis, and this process is achieved by gp120-induced activation of lysosome P2X4 via lysosome de-acidification and ATP enrichment. Currently, it is not clear how gp120 leads to lysosome de-acidification and ATP enrichment in Schwann cells. Given that gp120 has been shown to bind to CXCR4 receptors on Schwann cells ([@B62]) and that gp120 can be endocytosed and localized to lysosomes within 30 min ([Supplementary Figure S4B](#DS1){ref-type="supplementary-material"}) ([@B25]; [@B122]), gp120 could affect lysosome pH, lysosome ATP transport, and activity of lysosomal P2X4 either directly at the luminal side of lysosomes or indirectly via receptor-mediated signaling. Thus, further mechanistic studies are warranted.

The Functional Importance of gp120-Induced Lysosome Exocytosis in Schwann Cells {#S4.SS2}
-------------------------------------------------------------------------------

Schwann cells are the most abundant glial cells of the peripheral nervous system, ensheathing all axons of peripheral nerves as either myelinating or non-myelinating cells. In addition to its role as insulators of axons, Schwann cells are crucial for the proper function and maintenance of peripheral nerves by providing metabolic or trophic support ([@B10]; [@B32]; [@B104]) and modulating responses to nerve injury ([@B51]; [@B63]). On the other hand, the presence of axons is crucial to Schwann cells' ability to de-differentiate ([@B50], [@B110]; [@B91]). Thus, disrupting Schwann cell function can compromise glial--axon communication that can lead to disturbed nerve homeostasis and ultimately lead to fiber loss, neurodegeneration, and pain.

In the central nervous system, lysosomal exocytosis represents a new pathway for gliotransmitter secretion from astrocytes ([@B130]; [@B71]; [@B73]). In Schwann cells, lysosome exocytosis has also been demonstrated and plays an important role in regulating myelination ([@B20]; [@B107]; [@B57]; [@B114]). In particular, release of ATP via lysosome exocytosis has been demonstrated in Schwann cells ([@B107]). Numerous studies have shown the effect of extracellular ATP on Schwann cell physiology including its role on differentiation ([@B112]), activation ([@B99]), and its role in myelination ([@B48]) and in Wallerian degeneration ([@B107], [@B106]). The over-expression of P2X4 in Schwann cells have recently been shown to promote remyelination via secretion of brain derived neurotrophic factor ([@B114]), and another P2X receptor P2X7 has been shown to be involved in Charcot-Marie-Tooth disorder, a common inherited human neuropathy with demyelination ([@B90]). On the other hand, ATP is recognized as an important mediator of peripheral pain via activating the purinergic receptors and a rise in intracellular calcium in DRG neurons ([@B115]; [@B98]; [@B42]; [@B79]; [@B125]; [@B58]; [@B128]; [@B126]).

In the present study, we explored the effect of gp120-induced lysosome exocytotic release of ATP from Schwann cells on DRG neuron function by treating primary culture rat DRG neurons with conditioned media from gp120-treated rat Schwannoma cells. We demonstrated that conditioned media from gp120-treated rat Schwannoma cells induced a rise in the levels of intracellular calcium and increase in cytosolic ROS in DRG neuron, both of which have been implicated in the development of peripheral neuropathy and/or HIV DSP ([@B102]; [@B80]; [@B47]). Importantly, conditioned media from gp120-treated rat Schwannoma cells in the presence of P2X4 or VNUT antagonists failed to induce rises in calcium and ROS in DRG neurons. Given that blocking either P2X4 or VNUT in Schwann cell attenuated gp120-induced lysosome exocytosis and the release of ATP into media, our findings suggest that ATP released via lysosome exocytosis from Schwann cells induces calcium rise in DRG neuron. However, our findings could not exclude the involvement of other factors released via lysosome exocytosis from Schwann cells. For instance, Schwann cell exosomes have been shown to interact with axons, and increased miRNA455-3p induction has been shown to be associated with HIV DSP ([@B75]; [@B74]; [@B52]; [@B132]).

In summary, our findings suggest that HIV-1 gp120 promotes the movement of lysosomes toward plasma membrane followed subsequently by lysosomal exocytosis and the release of ATP; and this process is achieved by gp120-induced activation of lysosome P2X4 via lysosome de-acidification and VNUT coupling. Such gp120-induced lysosomal exocytosis from Schwann cells induces rises in cytosolic calcium and ROS in DRG neurons. Our results suggest that gp120-induced lysosomal exocytotic release of mediators including ATP from Schwann cells through P2X4 and VNUT signaling could be a possible mechanism for HIV-associated neuropathy. The mechanism identified here may have broader impact, because many viruses and bacteria enter host cells via endocytosis ([@B24]) and some viruses have been shown to release virions via lysosomal or autophagic exocytosis ([@B87]). It has been shown that virus-infected cells could release ATP that activates purinergic receptors on adjacent cells ([@B116]; [@B76]) and affect viral infections including HIV, hepatitis virus, influenza, and dengue viruses ([@B118]; [@B23]; [@B70]). Similar to viruses themselves, viral proteins such as HIV-1 Tat protein has been shown to enter cells via endocytosis ([@B34]) and promote lysosome exocytosis ([@B31]). However, the potential role of virus or viral proteins in regulating purinergic receptors on lysosomes has not yet been studied. Thus, our findings provide a novel mechanism whereby viral proteins could affect lysosome purinergic receptors once entering the cell, and such a mechanism could occur in many other infectious diseases.
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